Annals of the Russian academy of medical sciencesAnnals of the Russian academy of medical sciencesВестник Российской академии медицинских наук0869-60472414-3545"Paediatrician" Publishers LLC19810.15690/vramn.v68i4.613SHORT MESSAGESКРАТКИЕ СООБЩЕНИЯINVESTIGATION OF POSSIBLE APPROACHES TO ANGIOGENESIS REGULATION IN VITRO WITH THE HELP OF RECOMBINANT FRAGMENTS OF ANGIOGENESIS INHIBITORS SUCH AS ENDOSTATIN, TUMSTATIN AND PEDFИЗУЧЕНИЕ ВОЗМОЖНОСТИ РЕГУЛЯЦИИ АНГИОГЕНЕЗА IN VITRO С ПОМОЩЬЮ РЕКОМБИНАНТНЫХ ФРАГМЕНТОВ ИНГИБИТОРОВ АНГИОГЕНЕЗА ЭНДОСТАТИНА, ТУМСТАТИНА И PEDFKuznetsovS. L.КузнецовС. Л.
Russian Federation

RAMS cor. member, Head of the Department of Innovative Development of Science Russian Academy of Medical Sciences Address: 109240, Moscow, Soljanka St., 14; tel.: 8(495) 698-56-31

kuznetsov@ramn.ruLikhvantsevaV. G.ЛихванцеваВ. Г.
Russian Federation

PhD, Professor, Department of Fundamental Medicine Lomonosov Moscow State University Address: 119192, Moscow Lomonosov Ave, 31/5; tel: (495) 932-88-14

info@fbm.msu.ruArutyunyanE. V.АрутюнянЕ. В.
Russian Federation

Ophthalmologist, City Hospital in Yubileiny Address: 141090, Moscow region, Yubileiny, Lesnaya St., 8/10; tel.: 8(498)-646-96-80

ev1012@ya.ruKuz'minK. A.КузьминК. А.
Russian Federation

Pathologist, Pathology Department of the Central Clinical Hospital Russian Academy of Sciences Address: 119333, Moscow, Litovskiy Blvd, 1A; tel.: (495) 921-34-74

info@fbm.msu.ruSel'kovS. A.СельковС. А.
Russian Federation

PhD, Professor, Head of the Immunology Laboratory, Research Institute of Obstetrics and Gynecology named after D.O. Otta Address: 199034, St. Petersburg, Mendeleev line 3; tel.: (812) 328-14-02

iagmail@ott.ruSokolovD. I.СоколовД. И.
Russian Federation

PhD, Head of the Group of Angiogenesis Study of Immunology Laboratory, Research Institute of Obstetrics and Gynecology named after D.O. Otta Address: 199034, St. Petersburg, Mendeleev line 3; tel.: (812) 328-14-02

iagmail@ott.ruSechenov First Moscow State Medical University, Russian FederationПервый Московский государственный медицинский университет им. И.М. Сеченова, Российская ФедерацияLomonosov Moscow State University, Russian FederationМосковский государственный университет им. М.И. Ломоносова, Российская ФедерацияD.O. Ott Research Institute of Obstetrics and Gynecology, St. Petersburg, Russian FederationНаучно-исследовательский институт акушерства и гинекологии им. Д.О. Отта, Санкт-Петербург, Российская Федерация14042013684Vestnik Rossiiskoi akademii medetsinskikh nauk / Annals of the Russian academy of medical sciencesВестник Российской академии медицинских наук636707082015Copyright ©; 1970, "Paediatrician" Publishers LLCCopyright ©; 1970, Издательство "Педиатръ"1970"Paediatrician" Publishers LLCИздательство "Педиатръ"https://vestnikramn.spr-journal.ru/jour/about/submissionshttps://vestnikramn.spr-journal.ru/jour/article/view/198

Neovascular diseases of visual organ such as age-related macular degeneration, retinopathy of prematurity, diabetic retinopathy, thrombosis of central retina vein and its branches, neovascular glaucoma, choroid and retina tumors have the leading positions in the list of ophtalmopatologies that result in blindness and incapacity. The variety of angiostatic medications of applied ophtalmology is scant. The aim of work was to study the possibile approaches to angiogenesis regulation in vitro with the help of recombinant fragments of natural inhibitors of angiogenesis such as endostatin, tumstatin and PEDF (pigment epithelial derived factor), and also their ability to be the base of potentially feasible and pharmacologically active substances. It is determined that endostatin, tumstatin and PEDF, as well as the comparison medication Bevacizumab in vitro have pro- or antiangiogenic influence. The direction of the biological effect depends on the cultivation conditions, peptide concentration in the cultural fluid and stage of angiogenesis.

Неоваскулярные заболевания органа зрения, такие как возрастная макулярная дегенерация, ретинопатия недоношенных, диабетическая ретинопатия, тромбозы центральной вены сетчатки и ее ветвей, неоваскулярная глаукома, опухоли хориоидеи и сетчатки, занимают лидирующие позиции в перечне офтальмопатологии, приводящей к слепоте и инвалидизации, а также к социальной и психологической дезадаптации. Арсенал ангиостатических препаратов в практической офтальмологии скуден. Цель настоящей работы заключалась в изучении возможности регуляции ангиогенеза in vitro с помощью рекомбинантных фрагментов природных ингибиторов ангиогенеза эндостатина, тумстатина и PEDF (pigment epithelial derived factor) и применения их в качестве потенциально возможных фармакологически активных субстанций. Установлено, что in vitro эндостатин, тумстатин и PEDF, как и препарат сравнения бевацизумаб, оказывают про- или антиангиогенное действие. Направленность биологического эффекта зависит от условий культивирования, концентрации пептида в культуральной жидкости и этапа ангиогенеза.

neovascular diseases of visual organinhibitors and stimulators of angiogenesisendostatintumstatinPEDFнеоваскулярные заболевания органа зрениястимуляторы и ингибиторы ангиогенезаэндостатинтумстатинPEDF1. Zhukov N.V. The current state of antianioennoy therapy. Target therapy without a target? Prakt. onkol. = Practical oncology. 2007; 8 (3): 164–170.2. Ziangirova G.G., Likhvantseva V.G. Osobennosti i rol' aniogeneza v opukholyakh. V knige: Opukholi sosudistogo trakta glaza [Features and Angiogenesis Role in Tumors. In: Tumors of Vascular Tract of the Eye]. Moscow, Poslednee slovo, 2003. 456 p.3. Ellington A.D., Szostak J.W. In vitro selection of RNA molecules that bind specific ligands. Nature. 1990; 346: 818–822.4. Eyetech Study Group: Preclinical and phase IA clinical evalution of anti-VEGF pegylatedaptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina. 2002; 22: 143-152.5. Folkman J. Tumor angiogenesis: Cancer Medicine. J.F. Holland, R.C. Bast, D.L. Morton, E. Frei, D.W. Kufe, R.R. Weichselbaum (eds.). Baltimore: Williams&Wilkins. 1997. P. 181–204.6. Paccola L, Costa RA, Folgosa MS, Barbosa JC, Scott IU, Jorge R. Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema IBEME study). Brit. J. Ophthalmology. 2008; 92: 76–80.7. Presta, L. G., Chen, H., O’Connor, S. J., Chisholm, V., Meng, Y. G., Krummen, L. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumor and other disorders. Cancer Res. 1997; 57: 4593–4599.8. Colella P., Corugno G., Auricchio A. Ocular gene therapy: current progress and future prospects. Trends in Molecular Medicine, 15 (1):, 2008; Р.23–31.9. Developments in Ophthalmology. Anti-VEGF. F. Bandello, M. BattagliaParodi (eds.). Karger–Basel. 2010. 144 p.10. Noel A., Lost M., Lambert V. Lecomte J., Marie Rakic J. Anti-angiogenic therapy of exudative ages macular degeneration:current progress and emerging concepts. Trends Mol. Med. 2007; 13 (8): 345–352.11. Lux A., Llacer H., Heussen F. et al. Non-responders to bevacizumab (Avastin) therapy of choroidalneovascular lesions. Brit. J. Ophthalmol. 2007; 91 (10): 1318–1322.12. Eghøj M.S., Sørensen T.L. Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab. Brit. J. Ophthalmol. 2011; 96: 21–23.13. Schaal S., Kaplan H.J., Tetzel T.H. Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration? Ophthalmology. 2008; 115: 2199–2205.